Malaysian Expert Consensus Guidelines for the Diagnosis and Management of Multiple Myeloma: A Modified Delphi Approach
Main Article Content
Abstract
The rising incidence of multiple myeloma (MM) in Malaysia, combined with limited access to newer therapies, highlights the need for locally adapted clinical guidance. This consensus aimed at establishing expert recommendations for the management of MM within Malaysia’s resource-variable healthcare system. A modified Delphi process was conducted with 11 haematologists. To inform evidence-based recommendations, a targeted literature review was performed from January 2012 to June 2025. These recommendations were then evaluated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria. A total of 58 consensus statements were developed across various areas, including diagnosis, staging, treatment of newly diagnosed and relapsed/refractory disease, renal impairment, infection prevention, high-risk smouldering myeloma, and supportive care. Agreement was assessed using a three-point Likert scale, with all statements achieving ≥ 80% consensus. Consensus recommendations highlighted that triplet induction remains the minimum standard for transplant-eligible patients in Malaysia. Quadruplet regimens deliver deeper responses and improved survival but are limited by regulatory and cost barriers across Asian health systems. In transplant-ineligible patients, treatment should be individualised based on age, frailty, cytogenetic risk, comorbidities, and financial considerations. Novel cellular and immune-based therapies, including CAR-T cells and bispecific antibodies, offer meaningful benefit in heavily pretreated disease, though availability remains restricted. Infection prophylaxis, immunoglobulin support, vaccination, and proactive management of myeloma-related bone disease are essential components of comprehensive care. Continued efforts to improve access to advanced diagnostics, novel therapies, and clinical trial participation will be critical to further enhance outcomes. This consensus provides a standardised, evidence-based framework to optimise MM care and improve patient outcomes nationally.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
National Comprehensive Cancer Network (NCCN). Multiple myeloma, version 1.2025. [Internet]. Plymouth Meeting (PA): NCCN; 2025. [Retrieved 2025 Feb 01]. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–779. https://doi.org/10.1002/ijc.33588
International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. [Internet]. Lyon: IARC; 2024. [Retrieved 2025 Nov 20]. Available at: https://gco.iarc.who.int/today
Diao X, Ben T, Cheng S, Niu S, Gao L, Xia N. Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021. BMC Public Health. 2025;25(1):1054. https://doi.org/10.1186/s12889-025-22240-2
Chng WJ, Nagarajan C, Huang SY, Malhotra P, Hwang YY, Blunk V, et al. A systematic review on the epidemiology and treatment options of multiple myeloma in Asia. Heliyon. 2024;10(21):e39698. https://doi.org/10.1016/j.heliyon.2024.e39698
de Mel S, Chen Y, Gopalakrishnan SK, Ooi M, Teo C, Tan D, et al. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. Singapore Med J. 2017;58(2):55–71. https://doi.org/10.11622/smedj.2016150
Cheong CS, Tengku KATAH, Anuar NA, Bee PC, Chin EFM, Khairullah S, et al. Treatment pattern and outcome of newly diagnosed multiple myeloma patients in a resource-limited setting. Asian Pac J Cancer Prev. 2024;25(2):595–601. https://doi.org/10.31557/APJCP.2024.25.2.595
Universiti Malaya. Universal in name, equitable in quality: Re-framing Malaysia’s public healthcare expenditure from spending to investment. [Internet]. Kuala Lumpur: Universiti Malaya; 2025. [Retrieved 2025 Dec 21]. Available at: https://swrc.um.edu.my/Reports%20and%20Books/Working%20Paper/WP3.3SEPT2025.pdf?_t=1760179094
Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802–1824. https://doi.org/10.1002/ajh.27422
Shang Z. Use of Delphi in health sciences research: A narrative review. Medicine. 2023;102(7):e32829. https://doi.org/10.1097/MD.0000000000032829
Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38. https://doi.org/10.1186/1472-6963-4-38
OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. [Internet]. 2011. [Retrieved 2025 Jan 10]. Available at: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
Tan D, Lee JH, Chen W, Shimizu K, Hou J, Suzuki K, et al. Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Leuk Lymphoma. 2018;59(10):2305–2317. https://doi.org/10.1080/10428194.2018.1427858
Dalkey N, Helmer O. The use of experts for the estimation of bombing requirements: a project Delphi experiment. Santa Monica (CA): RAND Corporation; 1951.
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–757. https://doi.org/10.1046/j.1365-2141.2003.04355.x
Nightingale B, Decker M, Ryan R, Kaczmarczyk K, Jandir P, Waykole T, et al. Multiple myeloma: a review of the literature and a case report highlighting the immunocompromised state of myeloma patients. World J Oncol. 2024;15(3):348–354. https://doi.org/10.14740/wjon1780
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–2590. https://doi.org/10.1056/NEJMoa070389
Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018;32(8):1811–1815. https://doi.org/10.1038/s41375-018-0030-3
Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31(34):4325–4332. https://doi.org/10.1200/JCO.2012.48.4923
Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27(8):1738–1744. https://doi.org/10.1038/leu.2013.86
Cho J, Lee DH, Yoo G, Kim J, Uh Y. Comparison of serum and urine free light chain analysis in clinical diagnosis. Blood Res. 2022;57(4):284–289. https://doi.org/10.5045/br.2022.2022187
Oliveros Conejero R, Pascual Usandizaga P, Garrido Chércoles A. Optimization of workflow and screening panels for the detection of malignant monoclonal gammopathies. Adv Lab Med. 2020;1(3):20200042. https://doi.org/10.1515/almed-2020-0042
Putchen DD, Ramaprasad S. Laboratory approaches to enhance early detection of multiple myeloma and improve patient outcomes. J Diagn Acad Pathol. 2024;1(1):33–35. https://doi.org/10.4103/jdap.jdap_10_24
de Mel S, Tso AC, Soekojo CY, Ooi MG, Lim CC, Teo C, et al. Singapore Myeloma Study Group consensus guidelines for the management of patients with newly diagnosed multiple myeloma. Ann Acad Med Singap. 2025;54(9):561–584. https://doi.org/10.47102/annals-acadmedsg.202532
Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18):4701–4705. https://doi.org/10.1182/blood-2010-10-299529
Jimmy J, Jha V, Ajeesh G, Aryalakshmi B, Sidharthan N, Unni M. Clinical utility of 7-probe FISH panel in multiple myeloma in a resource-constrained setting: a retrospective and prospective observational study. Cancer Res Stat Treat. 2024;7(2):171–177. https://doi.org/10.4103/crst.crst_210_23
Bong IPN, Esa E. Molecular genetic aberrations in the pathogenesis of multiple myeloma. Asian Biomed (Res Rev News). 2023;17(4):152–162. https://doi.org/10.2478/abm-2023-0056
Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J. 2017;7(8):e599. https://doi.org/10.1038/bcj.2017.78
Talarico M, Barbato S, Cattabriga A, Sacchetti I, Manzato E, Restuccia R, et al. Diagnostic innovations: advances in imaging techniques for diagnosis and follow-up of multiple myeloma. J Bone Oncol. 2025;51:100669. https://doi.org/10.1016/j.jbo.2025.100669
Brieghel C, Slordahl TS, Andersen MN, Szabo AG, Niemann CU, Thorsteinsdottir S. A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2025;15(1):59. https://doi.org/10.1038/s41408-025-01268-y
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869. https://doi.org/10.1200/JCO.2015.61.2267
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. https://doi.org/10.1200/JCO.2005.04.242
D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406–3418. https://doi.org/10.1200/JCO.21.02614
Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21. https://doi.org/10.1038/s41408-022-00611-x
Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360–376. https://doi.org/10.1016/j.mayocp.2013.01.019
Cao Y, Gong Y, Zhou X, Sun C. Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients. Hematology. 2023;28(1):2208914. https://doi.org/10.1080/16078454.2023.2208914
Mohyuddin GR, Rubinstein SM, Kumar SK, Rajkumar SV, Fonseca R, Abdallah N, et al. Performance of newer staging systems for myeloma in a contemporary, large cohort of patients in the United States. Blood Cancer J. 2024;14(1):95. https://doi.org/10.1038/s41408-024-01076-w
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6
Kitundu JH. Redefining cure in multiple myeloma: are we chasing a moving target? Health Sci Rep. 2025;8(12):e71581. https://doi.org/10.1002/hsr2.71581
Rajkumar SV. Treatment of myeloma: cure vs control. Mayo Clin Proc. 2008;83(10):1142–1145. https://doi.org/10.4065/83.10.1142
Tschautscher MA, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, et al. Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer J. 2020;10(10):95. https://doi.org/10.1038/s41408-020-00363-6
Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801–1809. https://doi.org/10.1182/blood-2012-04-422683
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–2103. https://doi.org/10.1038/leu.2017.29
Kim HY, Yoo IY, Lim DJ, Kim HJ, Kim SH, Yoon SE, et al. Clinical utility of next-generation flow-based minimal residual disease assessment in patients with multiple myeloma. Ann Lab Med. 2022;42(5):558–565. https://doi.org/10.3343/alm.2022.42.5.558
Paiva B, Puig N, García-Sanz R, San Miguel JF. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? Clin Cancer Res. 2015;21(9):2001–2008. https://doi.org/10.1158/1078-0432.CCR-14-2841
Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059–3068. https://doi.org/10.1182/blood-2014-11-568907
Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–2464. https://doi.org/10.1182/blood-2018-06-858613
Moreau P, Rajkumar SV. Multiple myeloma--translation of trial results into reality. Lancet. 2016;388(10040):111–113. https://doi.org/10.1016/S0140-6736(16)30954-0
Derman BA, Jasielec JK, Jakubowiak AJ. Clinician attitudes and practices toward measurable residual disease in multiple myeloma. Br J Haematol. 2020;190(3):470–472. https://doi.org/10.1111/bjh.16805
Perrot A. Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myeloma. Presse Med. 2025;54(1):104262. https://doi.org/10.1016/j.lpm.2024.104262
Fu W, Li W, Hu J, An G, Wang Y, Fu C, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: updated analysis of LEPUS. Clin Lymphoma Myeloma Leuk. 2023;23(1):e51–e58. https://doi.org/10.1016/j.clml.2022.10.007
Kim JS, Song Y, Jen WY, Chim CS, Lee JJ, Yoon SS, et al. Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003). Blood Cancer J. 2025;15(1):155. https://doi.org/10.1038/s41408-025-01356-z
Teoh G, Chen Y, Kim K, Srivastava A, Pai VR, Yoon SS, et al. Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12(2):118–126. https://doi.org/10.1016/j.clml.2011.11.002
Zheng W, Wei G, Ye X, He J, Li L, Wu W, et al. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Leuk Res. 2009;33(12):1615–1618. https://doi.org/10.1016/j.leukres.2009.04.006
Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527. https://doi.org/10.1016/S0140-6736(16)31594-X
Wang YC, Lin CH, Su YC, Teng CJ. Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis. Hematology. 2025;30(1):2462249. https://doi.org/10.1080/16078454.2025.2462249
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023;24(1):64–76. https://doi.org/10.1016/S1470-2045(22)00693-3
Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, et al. Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation. Transplant Cell Ther. 2022;28(2):83.e1–83.e9. https://doi.org/10.1016/j.jtct.2021.10.022
Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024;8(23):5993–6002. https://doi.org/10.1182/bloodadvances.2024014139
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25(8):1003–1014. https://doi.org/10.1016/S1470-2045(24)00282-1
Pawlyn C, Menzies T, Davies FE, de Tute RM, Henderson R, Cook G, et al. Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant - data from the Myeloma XI Trial. Blood. 2022;140(Suppl. 1):1371–1372. https://doi.org/10.1182/blood-2022-165376
Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, et al. Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis. JAMA Oncol. 2018;4(10):1389–1397. https://doi.org/10.1001/jamaoncol.2018.2961
Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138(2):176–185. https://doi.org/10.1111/j.1365-2141.2007.06639.x
Ahmed A, Dima D, Row K, Ullah F, Awada H, Basali D, et al. Outcomes of salvage VDT-PACE-like regimens in relapsed-refractory multiple myeloma: 10-year experience of a large academic institution. Blood. 2023;142(Suppl. 1):4724–4724. https://doi.org/10.1182/blood-2023-182972
Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol. 2018;93(2):179–186. https://doi.org/10.1002/ajh.24954
Kaiser M, Pratt G, Bygrave C, Bowles K, Stern S, Jenner M, et al. Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: a British Society for Haematology/UK Myeloma Society good practice paper. Br J Haematol. 2024;205(3):833–839. https://doi.org/10.1111/bjh.19623
Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, et al. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. J Clin Oncol. 2023;41(23):3945–3955. https://doi.org/10.1200/JCO.22.02567
Moore S, Miller H, Parrish C, Seymour F, Miller L, Chandler T, et al. Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group. Br J Haematol. 2025;207(5):1789–1801. https://doi.org/10.1111/bjh.70041
Fonseca R, Rossi A, Medhekar R, Voelker J, Homan T, Wilcock J, et al. Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel. Future Oncol. 2024;20(23):1645–1656. https://doi.org/10.1080/14796694.2024.2342228
Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, et al. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39(4):942–950. https://doi.org/10.1038/s41375-024-02505-2
Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, van Beekhuizen S, et al. Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: a systematic literature review and network meta-analysis. Adv Ther. 2022;39(5):1976–1992. https://doi.org/10.1007/s12325-022-02083-8
Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7–15. https://doi.org/10.1182/blood-2011-06-357038
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976–4984. https://doi.org/10.1200/JCO.2010.30.8791
Soleymanian T, Soleimani A, Musavi A, Mojtahedi K, Hamid G. Outcome of patients with multiple myeloma and renal failure on novel regimens. Saudi J Kidney Dis Transpl. 2016;27(2):335–340. https://doi.org/10.4103/1319-2442.178557
Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, et al. Multiple myeloma therapy: emerging trends and challenges. Cancers. 2022;14(17):4082. https://doi.org/10.3390/cancers14174082
Fu C, Zhai Y, Yan L, Jin S, Shang J, Shi X, et al. Redefining multiple myeloma treatment: advances, challenges, and future directions in immunotherapy. Chin Med J. 2025;138(19):2399–2410. https://doi.org/10.1097/CM9.0000000000003655
Gengenbach L, Graziani G, Reinhardt H, Rösner A, Braun M, Möller MD, et al. Choosing the right therapy for patients with relapsed/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors. Cancers. 2021;13(17):4320. https://doi.org/10.3390/cancers13174320
Vera-Cruz S, Jornet Culubret M, Konetzki V, Alb M, Friedel SR, Hudecek M, et al. Cellular therapies for multiple myeloma: engineering hope. Cancers. 2024;16(22):3867. https://doi.org/10.3390/cancers16223867
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335–347. https://doi.org/10.1056/NEJMoa2303379
Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med. 2026;394(8):739–752. https://doi.org/10.1056/NEJMoa2514663
Martino EA, Carida G, Lofaro D, Bruzzese A, Labanca C, Mendicino F, et al. A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients. ESMO Open. 2025;10(8):105514. https://doi.org/10.1016/j.esmoop.2025.105514
Seehaus CM, Remaggi G, Filho JS, Ochoa P, Bigni R, de Magalhães RJP, et al. Burden of treatment, treatment sequencing and healthcare resource utilization in multiple myeloma in Latin America: a targeted literature review. Oncol Ther. 2026;14:113–154. https://doi.org/10.1007/s40487-025-00400-z
Tan CJ, Kacerek D, Kampirapawong N, Godara A, Chaiyakunapruk N. Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: a systematic review. Cancer Med. 2025;14(5):e70585. https://doi.org/10.1002/cam4.70585
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738. https://doi.org/10.1056/NEJMoa1903455
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275. https://doi.org/10.1038/s41375-019-0435-7
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371–1376. https://doi.org/10.1038/s41375-022-01531-2
Stalker ME, Mark TM. Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies. Curr Oncol. 2022;29(7):4464–4477. https://doi.org/10.3390/curroncol29070355
Tariq SM, Khalid MF, Noor J, Khamees I, Warraich SZ, Faisal MS, et al. Outcomes with non-BCMA CAR T cell therapy for multiple myeloma: a systematic review and meta-analysis. J Clin Oncol. 2025;43(16_Suppl):e19541. https://doi.org/10.1200/JCO.2025.43.16_suppl.e19541
Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143–e161. https://doi.org/10.1016/S2352-3026(21)00283-0
Lonial S, Bowser AD, Chari A, Costello C, Krishnan A, Usmani SZ. Expert consensus on the incorporation of anti-CD38 monoclonal antibody therapy into the management of newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(11):815–824. https://doi.org/10.1016/j.clml.2023.07.001
Lim KJC, Quach H. The role of intravenous immunoglobulin (IVIG) in reducing infection risk in multiple myeloma (MM) patients receiving immune-based therapies: a single center experience. Blood. 2023;142(Suppl 1):6671–6671. https://doi.org/10.1182/blood-2023-173893
Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38(11):1126–1137. https://doi.org/10.1200/JCO.19.01740
Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, Kastritis E, Terpos E, Dimopoulos MA, et al. Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies. Blood Cancer J. 2025;15(1):104. https://doi.org/10.1038/s41408-025-01312-x
Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59. https://doi.org/10.1038/s41408-018-0077-4
Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, et al. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. Hemasphere. 2024;8(3):e61. https://doi.org/10.1002/hem3.61
Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med. 2025;392(18):1777–1788. https://doi.org/10.1056/NEJMoa2409029
Mohan Lal B, Al Hadidi S. Daratumumab for high-risk smoldering multiple myeloma - Are we there yet? Eur J Cancer. 2025;220:115391. https://doi.org/10.1016/j.ejca.2025.115391
Mohyuddin GR, Chakraborty R, Cliff ERS, Derman BA. Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine. 2023;65:102272. https://doi.org/10.1016/j.eclinm.2023.102272
Bernstein ZS, Kim EB, Raje N. Bone disease in multiple myeloma: biologic and clinical implications. Cells. 2022;11(15):2308. https://doi.org/10.3390/cells11152308
Wang Y, Xu Q, Li Y, Su Y, Wang L, Wang X, et al. Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease. Cancer Pathog Ther. 2025;3(4):280–292. https://doi.org/10.1016/j.cpt.2024.12.002
Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e119–e130. https://doi.org/10.1016/S1470-2045(20)30559-3
Huang SY, Yoon SS, Shimizu K, Chng WJ, Chang CS, Wong RS, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, randomized controlled phase 3 study-Asian subgroup analysis. Adv Ther. 2020;37(7):3404–3416. https://doi.org/10.1007/s12325-020-01395-x
Dadana S, Gundepalli S, Kondapalli A. Severe refractory hypocalcemia caused by denosumab. Cureus. 2023;15(6):e39866. https://doi.org/10.7759/cureus.39866
LeBlanc R, Bergstrom DJ, Cote J, Kotb R, Louzada ML, Sutherland HJ. Management of myeloma manifestations and complications: the cornerstone of supportive care: recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) consensus guideline consortium. Clin Lymphoma Myeloma Leuk. 2022;22(1):e41–e56. https://doi.org/10.1016/j.clml.2021.07.028